Letters

More on peer reviewYour recent article on peer review1 omitted the fact that far too many journals do not report back to their reviewers. Only if a reviewer gets the decision letter plus the other reviews will he be able to learn and improve. Learning about the decision only when the paper makes it - or doesn't - to Medline is not sufficient.Manfred Gessler Theodor Boveri Institute for Life SciencesWuerzburg, Germanygessler@biozentrum.uni-wuerzburg.deYour

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Your recent article on peer review1 omitted the fact that far too many journals do not report back to their reviewers. Only if a reviewer gets the decision letter plus the other reviews will he be able to learn and improve. Learning about the decision only when the paper makes it - or doesn't - to Medline is not sufficient.

Manfred Gessler
Theodor Boveri Institute for Life Sciences
Wuerzburg, Germany
gessler@biozentrum.uni-wuerzburg.de

Your article1 and editorial2 on peer review make it clear that it is probably inevitable that the young, nonworking scientists who edit certain journals will find themselves unable to deal appropriately with a wide range of complex scientific topics, with famous and sometimes overbearing authors, and with equally famous and sometimes unethical reviewers.

Scientists themselves must shoulder some of the blame, however. It is a double embarrassment to modern science, especially biological-biomedical science, that the community has allowed itself to be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies